Travere Therapeutics Reports Q3 Revenue Beat Amid Non-GAAP EPS Miss
Travere Therapeutics (TVTX) reported third-quarter financial results characterized by a significant revenue beat alongside an earnings miss. The company generated $224.5 million in revenue, representing a 36.1% increase year-over-year and exceeding analyst expectations by $29.21 million. However, the company's Non-GAAP earnings per share (EPS) came in at -$0.31, missing consensus estimates by $0.73. On a non-GAAP adjusted basis, R&D expenses for the third quarter were reported at $63.2 million.
Tickers: $TVTX